Results from a new phase 1 trial indicate that immunotherapy could be used to treat the most common form of colorectal cancer, also known as bowel cancer. Consistent responses to immunotherapy have been reported in patients with the most common type of colorectal tumors, known as MSS mCRC, with 61% of patients seeing their tumor shrink or remain stable after receiving treatment.
